A mathematical model using data from routine diagnostic samples has been found to accurately predict individual patient responses to the main candidate first-line treatments for acute myeloid leukemia.

Findings from a validation study in independent patient cohorts led by researchers from the Barts Cancer Institute at the Queen Mary University of London were reported at a poster session of the 2024 ASCO Annual Meeting.

Oncology Times correspondent Peter Goodwin attended the session and talked with the second author of the study, Weronika E. Borek PhD, a Bioinformatics Technical Lead at Kinomica Limited in London.